![Eyes](/sites/default/files/styles/hero_homepage/public/2022-08/Eyes.png?itok=p6dUibdH)
Reinventing the discovery, development, and commercialization of new medicines
We develop transformative medicines and technologies by building agile, focused companies called Vants.
10
positive Phase 3 trials since 2019
06
FDA approvals
01
Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.
We employ technology across discovery, development, and commercialization.
![video section decoration](/themes/custom/roivant/images/video-decoration.png)
Roivant Overview - JP Morgan Healthcare Conference 2024
Read the latest from Roivant and the media.
![For Investors](/sites/default/files/styles/teaser/public/2022-10/forinvestors.png?h=a727d99f&itok=n-YBbx0F)
Learn more about our work
Sign up for our latest announcements and upcoming presentations
![Pipeline](/sites/default/files/styles/teaser/public/2022-10/pipeline.png?h=a727d99f&itok=FT9pwpRg)
Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.